Stock AnalizBiogen Inc. BIIB
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Biogen Inc. (BIIB) is a healthcare company listed in the US with a market value of about $37.5B. In the twelve months to September 30, 2026 it had revenue of $10.3B and net income of $348M, a net margin of 3.4%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (1/5).
Key numbers: a P/E of 109.2, a price to free cash flow of 18.1, 5-year revenue growth of -6% a year, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 33% below the current price.
Score: 1.8 / 5
Checks passed
- P/FCF below 20
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.3B | $9.9B | $9.7B | $9.8B | $10.2B | $11.0B | $13.4B | $14.4B | $13.5B | $12.3B | $11.4B |
| Net income | $348M | $1.3B | $1.6B | $1.2B | $3.0B | $1.6B | $4.0B | $5.9B | $4.4B | $2.5B | $3.7B |
| Free cash flow | $2.1B | $2.1B | $2.7B | $1.3B | $1.1B | $3.4B | $3.8B | $6.6B | $5.4B | $3.7B | $4.0B |
| EPS (diluted) | $2.32 | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.93 |
| Net margin | 3.4% | 13.1% | 16.9% | 11.8% | 29.9% | 14.2% | 29.8% | 41.0% | 32.9% | 20.7% | 32.3% |
| ROIC | — | 5.2% | 7.0% | 5.2% | 14.7% | 13.9% | 19.6% | 27.7% | 23.4% | 15.0% | 20.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 32 analysts is $268.26, 6% above the current price; targets range from $175.00 to $350.00; the consensus rating is “Buy”; expected EPS is $12.53 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Biogen’s P/E ratio?
About 109.2, based on the last twelve months of diluted earnings per share (forward P/E about 17.4).
Is Biogen stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 33% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Biogen pay a dividend?
Not currently.
Is Biogen a good stock to buy?
We do not give buy or sell advice. Biogen scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.